DFTX
Healthcare BiotechnologyDefinium Therapeutics, Inc.
$37.40
+0.18 +0.48% today
Price History
Not enough data
Key Stats
Market Cap
5.03B
Avg Volume
2.14M
EPS
-$3.43
52W High
$49.70
52W Low
$10.47
Div. Yield
0.0%
Analyst Ratings
Buy4
Str Buy
14
Buy
0
Hold
0
Sell
0
Str Sell
Valuation
Forward P/E
-19.66
P/B Ratio
5.47
Margins
Gross Margin 0.0%
Operating Margin 0.0%
Net Margin 0.0%
EBITDA Margin 0.0%
Growth & Returns
Return on Equity
(64.1%)
Return on Assets
(20.6%)
Liquidity & Leverage
Current Ratio
6.95
Quick Ratio
6.89
Debt / Equity
0.04
Total Cash
1.08B
Total Debt
36.47M
About
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
definiumtx.com